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1. INTRODUCTION 
Protein kinase C (PKC), a multifunctional 
serine/threonine protein kinase, plays crucial roles in 
signal transduction [I]. The enzyme requires Ca’” and 
phospholipid, particularly phosphatidylserine for its 
activation. Under physiological conditions 
diacylglycerol greatly increases the affinity of PKC for 
Ca2’ and phospholipid, thereby activating the enzyme. 
Although the receptor-nlediated hydrolysis of inositol 
phospholipids was once thought to be the sole 
mechanism leading to the activation of PKC, recent 
studies suggest the existence of several other routes to 
provide the diacylglycerol that is needed for enzyme ac- 
tivation. In addition, it is now clear that there are 
multiple subspecies of PKC with closely related struc- 
tures but subtly different properties and perhaps with 
different physiological functions. While the extent of 
the diversity of the PKC family is not fully clarified at 
present, some aspects of current studies and the pro- 
spective of this enzyme family wili be briefly discussed. 
2. ~~OL~~ULAR H~T~RO~~NEITY AND 
STRUCTURES 
Molecular cloning and biochemical analysis have 
revealed the enzyme to exist as a family of multiple 
subspecies having closely related structures (see 121 for 
a review). Initially, four cDNA clones, M, $1, ,Bli and 
3 were isolated [3-S]. The enzymes with dl- and $II- 
sequence are derived from a single RNA transcript by 
alternative splicing [8]. Each of the four PKC 
subspecies consists of a single polypeptide with foul 
conserved (Cl-C4) and five variable (VI-VS) regions. 
The amino-terminal half, containing region Cl and C2, 
is the regulatory domain that interacts with Cal’, 
phospholipid and diacylglycerol or phorbol ester. The 
region Cl contains a tandem repeat of a cysteine-rich 
zinc-finger-like sequence. This sequence seems to be 
essential for the binding of phorbol ester, and possibly 
by analogy diacylglycerol, implying its involvement in 
the membrane-PKC interaction [9]. The region C2 may 
be necessary for the Cal+ sensitivity of the enzyme [lo]. 
The carboxyl-terminal half, containing region C3 and 
C4, is the protein kinase domain that shows sequence 
homology with many other protein kinases. The region 
C3 involves the catalytic site of the enzyme. 
Another group of cDNA clones, encoding at least 
three further subspecies that have the 6-, c- and J”- 
sequence, have also been isolated from the rat brain 
library [l l-131. The members of this group lack region 
C2 of the regulatory domain. The trarislatio~~~~l pro- 
ducts of 6-, f- and f-cDN.4 expressed in COS ceils do 
not require Ca”+ for their enzymatic activity [12-141. 
The molecular mass of i-subspecies is smaller (64 kDa) 
than that of the others (approximately 80 kDa), since 
this subspecies contains only one Lint-finger-like se- 
quence in region Cl. 
Although the biochemical mechanism of PKC activa- 
tion has not yet been fully clarified, the activity of this 
enzyme appears to be normally covered by interaction 
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between the catalytic and regulatory domains. It has 
been proposed that a small part of the amino-terminal 
region of the regulatory domain encodes a unique se- 
quence, termed ‘pseudosubstrate’ [ 1.51. This sequence 
has a strong affinity to the active site of the enzyme. A 
synthetic peptide containing the pseudosubstrate se- 
quence has been shown to be a potent inhibitor of 
PKC, while this peptide becomes an excellent substrate 
for the enzyme when the alanine in this sequence is 
replaced by serine. The proteins which are capable of 
serving as substrates for PKC normally contain basic 
amino acids such as arginine or lysine at the carboxyl- 
terminal side adjacent to the seryl or threonyl residue 
to be phosphorylated [l&19]. The antibody directed 
against this pseudosubstrate peptide has been shown to 
activate PKC in the absence of Ca2+, phospholipid and 
diacylglycerol [20]. 
3. DIFFERENTIAL DISTRIBUTION AND 
PROPERTIES 
The diversity of the sequence in the variable regions 
allows separation of PKC into several subfractions by 
chromatography on a hydroxyapatite column [21-233. 
Three subfractions, type I, II and III, have been obtain- 
ed which correspond to y-, fi (,&I + ,&I)- and a- 
subspecies, respectively [22,24]. With the aid of 
biochemical, immunohistochemical and in situ 
hybridization procedures the relative activity and in- 
dividual pattern of expression of multiple PKC 
subspecies in several tissues and cell types has been ex- 
amined extensively (see 121 for a review). 
PKC with the y-sequence (type I) is expressed ex- 
clusively in the central nervous system, and the highest 
enzyme activity has been found in the hippocampus, 
cerebral cortex, amygdaloid complex, cerebellar cortex 
and spinal cord [25,26]. This PKC subspecies is 
associated with most of the membranous structure, 
particularly in the hippocampal pyramidal cell and 
Purkinje cell. The enzyme is poorly expressed in the 
nerve endings which terminate on these cells, implying 
that this PKC subspecies plays roles in the post- 
synaptic processes in these cell types. 
Perhaps the most striking feature of the y-subspecies 
is that this enzyme can be activated in vitro by 
micromolar concentrations of free arachidonic acid 
and some of its metabolites such as lipoxin A (see [2] 
for a review). This activation does not require Ca2” and 
phospholipid. The second messenger role of 
arachidonic acid and its metabolites, however, has not 
yet been established. 
PKCs with the ,!.?‘I- and ,&I-sequences (type II) are 
present in variable ratios in many tissues and cell types 
jncluding the brain. Normally, the amount of the @II- 
subspecies far exceeds that of the ,&I-subspecies. These 
two subspecies differ from each other only in their 
carboxyi-terminal end-region corresponding to V5. In 
certain tissues such as cerebellar cortex, a distinct 
cellular expression of these two enzymes is apparent 
[2]. In neuronal cells, the PI-subspecies is sometimes 
associated with plasma membranes, whereas the pII- 
subspecies is often localized in the Golgi complex (see 
[2,27] for reviews). PKC with the P-sequence has been 
shown to exhibit a significant activity in the absence of 
added CaZ+, although the Ca2+ dependence depends 
largely on the phosphate acceptor protein employed 
1281. 
PKC with the a-sequence (type III) is widely 
distributed in many tissues and cell types. It is the most 
sensitive to diacylglycerol for activation. Some cell 
types such as NIH 3T3 fibroblasts [29] and COS cells 
IS] express only the cw-subspecies, but most cells so far 
examined including T-lymphocytes [30-321 and HL-60 
cells [33] co-express several PKC subspecies in different 
ratios. Several PKC subspecies, by light-microscopy 
resoiution, apparently show distinct intracelluiar loca- 
tions, depending upon the state of differentiation or 
proliferation. 
At present, the distribution and biochemical proper- 
ties of the enzymes encoded by the S-, F- and j--sequence 
have not been determined. These subspecies have been 
expressed in COS cells, but their correspondence to 
subfractions obtained by chromatography from tissues 
has not been identified. Histone is usually a poor 
substrate for this subgroup of enzymes. 
In addition to the PKC family described above, 
several structurally undefined subspecies have been 
isolated from various tissues such as adrenal cortex 
[34], platelets 1351 and HL-60 cells (331, which respond 
to Ca”, phospholipid and diacylglycerol in different 
ways. A fraction of enzyme, which is phospholipid- 
dependent but is inhibited by Cazf, has been obtained 
from rat brain tissues (361. Several PKC subspecies so 
far isolated from many tissues and cell types exhibit 
subtly different kinetic properties and substrate 
specificities [28,34,37]. In short, mammalian tissues 
and organs appear to contain a variety of PKC 
subspecies, but the extent of this diversity is not fully 
clarified at present. 
The enzyme has been found also in lower organisms 
including Drosophila [38,39], Xenopus faevis [40], sea 
urchin egg [41], Dictyostelium discoideum [42,43] and 
Saccharomyces cerevisiae [44] as determined by 
molecular cloning analysis. It is worth noting that the 
recently isolated yeast enzyme shows a substrate 
specificity entirely different from that of mammalian 
PKC [45]. The enzyme shows characteristics similar to 
mammalian PKC, and is activated by diacylglycerol but 
not by phorbol esters [45]. 
4. SIGNAL ROUTES FOR ACTIVATION AND 
DOWN-REGULATION 
Although the receptor-mediated hydrolysis of in- 
351 
Volume 568, number 2 FEBS LETTERS August 19w 
Fig. I. Signal routes for PKC activation. ‘The detailed cxpianarion is 
given in rhe text. Pt. phospbatid~linosirol and its mono- and bis- 
phoiphate; PC, phosphatidvlcholine; DG, diacylglycerol; and 
NMDA, h’-meth~t-D-aspartate. 
ositol phospholipids was once thought to be the sole 
mechanism leading to the activation of PKC [I], recent 
studies suggest that there are several additional routes 
to provide the diacylglycerol that is needed for enzyme 
activation, as schematically given in Fig. 1. For in- 
stance, phosphatidylcholine may also be hydrolysed to 
produce diacyiglycerol at a relatively later phase of 
cellular responses, particularly those to long-acting 
signals such as some growth factors (see [46,47] for 
reviews). For instance, early studies with T- 
lymphocytes have suggested that interleukin-1, an ac- 
cessory signal to cell activation, stimulates the produc- 
tion of diacylglyc~rol from phospllatidylcholine 1481. 
However, several isoforms of the Ca*+-dependent 
phosphoIipase C so far identified do not react with 
phosphatidylcholine, and it has been postulated that 
phospholipase D followed by phosphatidic acid 
phosphatase may be involved in such receptor- 
mediated phospholipid degradation. In fact, agonist- 
stimulated activation of phospholipase D has been 
shown in several tissues and cell types such as 
hepatocytes 1491, HL-60 cells [SO,Sl], platelets 1521 and 
fibroblasts [.53], although the precise mechanism of this 
activation remains to be explored. It is possible that 
PKC itself may take part in this phospholipid degrada- 
tion cascade. 
In addition, both receptor-mediated and voltage- 
dependent Ca’i-gate opening may cause pll~spholipid 
degradation, that is probably initiated by the activation 
of phosphofipase C and also pilosphoiipases D and AZ 
due to the Ca”+-influx. As briefly noted above, 
arachidonic acid and its metabolites are able to activate 
some subspecies of PKC under certain conditions. 
Thus, the signal routes leading to the activation of PKC 
may greatly vary with cell types, extracellular signals, 
and perhaps with the time after cell stimulation. 
The enzyme was originally detected as an undefined 
protein kinase which was activated by limited pro- 
teolysis with calpain, a Ca’+-dependent neutral pro- 
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tease [54]. Indeed, PKC is very susceptible to limited 
proteolysis. This reaction generates a catalytically fully 
active fragment, previously called protein kinase M 
[55]. A protein kinasc known for a long time as histone 
kinase II has been proved to be the proteolyt~cally ac- 
tivated fragment of PKC [ 181. Calpain I, that is active 
in the micromolar range of CaZt concentrations, 
cleaves preferentially the active form of PKC 1561. In 
in vitro systems, PKC subspecies with the a-, d- and 2- 
sequence are cleaved at different rates at one or two 
specific sites in region V3, that connects the regulatory 
and protein kinase domains. 
Although the physiological significance of this 
Iimited proteolysis has not been established, it is possi- 
ble that this reaction is a process for activating PKC 
persistently as postulated in platelets and neutrophils 
157,581. Alternatively, the proteolysis may also be a 
process for initiating the degradation, termed down- 
regulation, of the PKC molecule itself [59-621. In most 
cells, the catalytically active fragment is not always 
recovered from the cell, and is probabIy degraded fur- 
ther by the action of other proteases [56]. In fact, on 
treatment with phorbol esters, several PKC subspecies 
co-expressed in a single cell disappear at different rates, 
which may reflect their susce~~t~bil~ty to the calpain ac- 
tion [63,64]. 
5. PHYSIOLOGICAL ROLES FOR CELLULAR 
REGULATION 
it is well recognized that the synergistic interaction 
between PKC and CaZ” pathways underlies a variety of 
cellular responses to external stimuli (see [I ,651 for 
reviews). Although studies on the detailed biochemical 
action of individual PKC subspecies are only at their 
outset, one can anticipate that members of the family 
may each have different roles in the processing and 
modulation of a wide variety of cellular functions. Up 
to now, many physiological functions have been assign- 
ed to PKC, inc1L~diI~g involvement in secretion and 
release of various cellular constituents from endocrine, 
exocrine and neuronal tissues, smoorh muscle contrac- 
tion and metabolic processes such as steroidogenesis 
1341. 
Major roles of PKC appear to lie in positive and 
negative interactions with various ion channels (f66]* 
also see [67] for a review) and other cell-signalling 
pathways involving Ca“ and cyclic AMP (see 12,651 
for reviews). A large body of evidence also indicates 
that PKC exerts negative-feedback control or down- 
regulation of various receptors, that are coupled to in- 
ositol phospholipid hydrolysis, and those of some 
growth factors (see [2,&S] for reviews). Epidermal 
growth factor receptor (see [6X] for a review) and T-cell 
surface CD3 complex [69] arc typical examples. 
Presumably, some coupling factor in membranes is a 
possible target of PKC action 1701. 
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Fig. 2. Hypothetical signal cascades involving various protein 
kinases, eventually leading to gene activation and cell cycle control. 
Search has been made in recent years to elucidate a possible link 
between various growth factor receptors having direct or indirect 
tyrosine kinase and serine/threonine kinase activities. MAP I1 
kinase, microtubulus-associated protein II kinase; PKA, cyclic AMP- 
dependent protein kinase; Ca’ CaM-dept. PK, Ca” and calmodulin- 
dependent protein kinase. 
On the other hand, it is becoming clearer that PKC 
may play roles of crucial importance for the regulation 
of gene expression and cell proliferation. Apparently, 
sustained activation of PKC is needed to cause gene ac- 
tivation, eventually leading to cell proliferation. It has 
recentiy been demonstrated that, with purified T-cells, 
multiple and repeated additions of membrane- 
permeable diacylglycerol result in both interleukin-2 
receptor expression and cell proliferation (71,721. 
Unlike phorbot esters which activate PKC persistently 
1731, a single dose of permeable diacylgIycero1, which 
causes only transient activation of PKC, cannot elicit 
T-cell activation [31]. The cell activation and prolifera- 
tion process is obviously the result of an interaction of 
a number of signalling pathways. One of these is PKC 
activation, which is required for a prolonged length of 
time, brought about, physiologically, by a combination 
of various signals involving the phospholipid degrada- 
tion cascade discussed above. This may be needed for 
maintenance of phosphorylation of a protein whose ac- 
tivity is critical in the regulation of gene activation, 
such as transcription factors. Presumably, the signall- 
ing pathways, including tyrosine kinases and 
Ca2+-dependent kinases, may play critical roles in this 
process. Recently, considerable interest has centered on 
cross-talk between a variety of different protein kinases 
in a direct or indirect fashion as schematically given in 
Fig. 2 (see also [74] for a review). It has been proposed 
that integration of two signalling pathways involving 
tyrosine and serine/threonine kinases is needed for ac- 
tivation of a protein kinase, MAP kinase 1751. It is like- 
ly then, that gene activation and cell proliferation may 
result from dynamic interactions between PKC and 
many other signalling pathways. 
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